Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

5(56%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

11%

Ph phase_3

22%

Ph phase_1

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

6(66.7%)

Phase 2Efficacy & side effects

1(11.1%)

Phase 3Large-scale testing

2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Completed(4)

Detailed Status

Recruiting5

Completed4

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 16 (66.7%)

Phase 21 (11.1%)

Phase 32 (22.2%)

Trials by Status

completed444%

recruiting556%

Recent Activity

5 active trials

Showing 5 of 9

recruitingphase_3

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

NCT06136624

recruitingphase_3

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650

recruitingphase_1

A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)

NCT07548606

completedphase_1

A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)

NCT06104449

recruitingphase_1

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

NCT06353386

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT06136624Phase 3

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Recruiting

NCT06136650Phase 3

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Recruiting

NCT07548606Phase 1

A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)

Recruiting

NCT06104449Phase 1

A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)

Completed

NCT06353386Phase 1

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

Recruiting

NCT06979596Phase 2

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

Recruiting

NCT06136598Phase 1

A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)

Completed

NCT06860243Phase 1

A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)

Completed

NCT06633419Phase 1

A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)